Clinical Management of DMD-Associated Cardiomyopathy by Lee-Gannon, Theo et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books







Clinical Management of  
DMD-Associated Cardiomyopathy
Theo Lee-Gannon, Hannah Lehrenbaum, Rahul Sheth  
and Pradeep P.A. Mammen
Abstract
Over the past decade, cardiomyopathy has become the leading cause of  mortality 
among patients with Duchenne muscular dystrophy (DMD). The majority of DMD 
patients over the age of 18 experience some degree of cardiac involvement. The 
primary cardiac manifestations of DMD include progressive left ventricular (LV) 
wall stress leading to LV dilatation and wall thinning, and the development of 
cardiac fibrosis, all of which culminate in decreased LV contractility and reduced 
cardiac output. Mortality in these patients is predominantly related to pump failure 
and fatal arrhythmias leading to sudden cardiac death. While basic guidelines for 
the management of cardiomyopathy in DMD patients exist, these recommendations 
are by no means comprehensive, and this chapter aims to provide further insight 
into appropriate clinical diagnosis and management of DMD-associated cardiomy-
opathy. Notably, earlier and more frequent cardiac assessment and care can allow 
for better outcomes for these patients. Pharmacological treatments typically include 
an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker, 
beta-adrenergic receptor blockers, mineralocorticoid receptor antagonists, and 
corticosteroids. Non-pharmacological therapies include automated implantable 
cardioverter defibrillators and left ventricular assist devices, as well as in rare cases 
cardiac transplantation. Additionally, many emerging therapies show great promise 
for improving standards of care. These novel therapies, based primarily on applied 
gene therapy and genome editing, have great potential to significantly alter the 
DMD care landscape in the near future.
Keywords: DMD-associated cardiomyopathy, Duchenne muscular dystrophy, 
dystrophinopathy, heart failure
1. Introduction
Duchenne muscular dystrophy (DMD) is a progressive neuromuscular disor-
der diagnosed during childhood and characterized by skeletal muscle wasting, 
diaphragmatic weakness and scoliosis resulting in chronic restrictive lung disease, 
and progressive cardiomyopathy. As an X-linked recessive disorder, DMD dispro-
portionately impacts males compared to females and affects approximately 1 in 
every 3500 to 5000 live male births [1–3]. The disease is caused by mutations in the 
dystrophin gene located on the Xp21 chromosome, resulting in a lack of a functional 
dystrophin protein [4, 5]. While other dystrophinopathies result in a truncated but 
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partially functional dystrophin protein, the total absence of functional dystrophin 
protein in DMD patients leads to a myriad of devastating clinical outcomes.
Over the past several decades, significant progress has been made in treating and 
managing many of the complications in DMD. Although respiratory failure was his-
torically the leading cause of morbidity and mortality in this population, advance-
ments in nocturnal ventilatory support and spinal stabilization therapy have 
dramatically improved clinical outcomes and increased the average life expectancy 
of DMD patients [6]. As a result, more patients are living into adulthood where 
cardiomyopathy begins to manifest and now accounts for the majority of deaths 
[1, 4, 6, 7]. Although there is ongoing research in gene therapy and genome editing 
techniques to improve skeletal muscle function in DMD patients, cardiomyopathy 
among DMD patients remains a problem of paramount clinical significance, with 
the current focus on reducing cardiac involvement and mitigating the effects of the 
cardiomyopathy. This chapter will highlight the genetic and molecular pathology 
underlying DMD and provide insight into the clinical manifestations, diagnosis, 
treatments, and therapies for DMD-associated cardiomyopathy.
2.  Genetics and the molecular basis underlying cardiac dysfunction in 
Duchenne muscular dystrophy
The dystrophin gene is the largest protein-coding gene in the human genome at 
2.5 Mb, located on chromosome Xp21.1 [1, 5, 8]. With 79 exons and a 14-kb encod-
ing transcript, the gene has four promoters which produce different isoforms of 
the dystrophin protein in various organs, but primarily in skeletal muscle, cardiac 
muscle, and the brain (Figure 1A) [8]. Frame shift mutations resulting in deletions 
of one or more exons of the gene are the most common cause of DMD, accounting 
for at least 65-75% of DMD cases [9, 10]. Duplications, deep intronic changes, non-
sense mutations, and missense mutations can also disrupt dystrophin expression 
and lead to DMD [9], though these mutations occur less commonly. The phenotypic 
manifestations of DMD occur when these mutations result in a complete lack of 
functional dystrophin protein. While most instances of DMD are inherited, around 
30% of cases are caused by spontaneous mutations in the gene [1, 11].
The dystrophin protein plays an integral role in maintaining myocyte membrane 
stability, connecting the dystrophin-associated glycoprotein complex (DGC) to the 
intracellular contractile apparatus and extracellular matrix of the cell (Figure 1B)  
[1, 4, 12, 13]. An absence of dystrophin protein destabilizes this complex and 
promotes sarcolemmal fragility. In the skeletal muscle of DMD patients, this leads 
to the loss of the majority of the DGC. In contrast, cardiac muscle retains the 
remainder of the DGC despite the absence of dystrophin. Despite these pathophysi-
ological differences, both skeletal and cardiac muscle are drastically impacted by 
the absence of dystrophin protein. Specifically, in cardiac muscle the absence of 
dystrophin impacts the ability of myocytes to function properly and leads to many 
secondary pathophysiological mechanisms of cell degradation [1, 4, 14].
One such mechanism contributing to myocyte degradation involves the disrup-
tion of ion gradients. As the myocyte membrane weakens due to the absence of 
dystrophin, calcium passively leaks through the membrane; the activation of sarco-
lemmal stretch-activated channels during myocyte contraction causes intracellular 
calcium levels to further increase [4, 15]. Additionally, transient receptor potential 
(TRP) channels and L-type calcium channels (LTCC) have been shown to contrib-
ute to increased intracellular calcium in DMD murine studies [16–18]. Increased 
intracellular calcium ultimately results in myocyte degradation through two distinct 
pathways. First, electrical and contractile activities of myocytes are interrupted by 
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the inappropriate influx of calcium, promoting proteolytic activity via proteolytic 
enzymes and calpains, which eventually leads to cell death [15–17]. A secondary 
degradation pathway is triggered when excess cytosolic calcium begins to accumu-
late inside mitochondria, resulting in mitochondrial swelling and dysfunction that 
triggers separate apoptotic pathways [17]. Cardiac physiological studies on DMDmdx 
mice have demonstrated elevated levels of mitochondrial calcium and mitochon-
drial swelling, leading to a disruption in mitochondrial ATP production in DMDmdx 
hearts long before any fibrotic changes or reductions in left ventricular (LV) systolic 
function are detectable [4, 15–17].
In addition to calcium gradient disruption, increased generation of reac-
tive oxygen species (ROS) and nitric oxide dysregulation also contribute to the 
development of DMD-associated cardiomyopathy. NADPH oxidase 2 (NOX2) is 
a membrane-bound isoform of the NOX enzyme, and it is the suspected source 
of increased ROS production in DMD patients. Elevated expression of NOX2 
has been demonstrated in studies of both skeletal muscle and cardiomyocytes 
of DMDmdx mice [19]. It has additionally been speculated that ROS produced by 
NOX2 may contribute to calcium leakage from the sarcoplasmic reticulum leading 
to mitochondrial dysfunction [4, 19, 20]. Activation of NOX2 leads to the produc-
tion of an extracellular superoxide, which is then converted to hydrogen peroxide 
(H2O2). H2O2 is able to permeate through the myocyte membrane and results in the 
oxidation of various intracellular macromolecules, eventually leading to secondary 
Figure 1. 
Dystrophin structure and cellular location within a myocyte. (A) the dystrophin gene map composed of 79 
exons and the essential regions highlighted in various colors. (B) Schematic of the dystrophin-associated 
glycoprotein complex (DGC). Adapted from Zhang et al. Physiolo. Rev 2018 98:1205-1240.
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pathways contributing to cell death [4, 21]. Finally, angiotensin II receptor type I 
(AT1R) is believed to be involved in redox pathways involving the stimulation of 
NADPH oxidases, such as NOX2, and so the overproduction of ROS can lead to the 
overstimulation of AT1R. These events lead to further oxidative stress resulting in 
increased cardiomyocyte cell death [21].
Nitric oxide synthases (NOS) are a family of enzymes that catalyze the produc-
tion of nitric oxide. There are three isoforms of NOS: neuronal NOS, endothelial 
NOS, and inducible NOS. In skeletal muscle, dystrophin interacts with neuronal 
NOS to control vasculature [22]. The relationship between dystrophin and NOS 
is less clear in the myocardium, especially since all three isoforms of NOS are 
expressed within cardiomyocytes and the molecular mechanisms and interactions 
have not been well elucidated to date [4]. It is speculated that NOS may play a simi-
lar role in cardiomyocytes as in skeletal muscle, and that in affected DMD patients 
nitric oxide diffusion is impaired. Researchers believe that inducible NOS may play 
a key role in the development of cardiac dysfunction in DMD, since its expression 
is high in immune cells and studies have found elevated inducible NOS levels and 
decreased neuronal NOS levels in cardiac tissue, while endothelial NOS levels and 
activity were reported to remain fairly constant [4, 22].
Collectively, these mechanisms involving altered ion gradients, mitochondrial 
dysfunction, and impaired nitric oxide activity contribute to pathways that promote 
cardiomyocyte dysfunction and cell death. The inflammatory responses to these 
processes ultimately lead to the development of myocardial fibrosis and maladap-
tive ventricular remodeling [9, 23]. Fibroblasts, endothelial cells, immune cells, 
and cardiomyocytes all contribute to the development of fibrosis by promoting 
profibrotic cytokines and chemokines. Fibrotic infiltration typically begins in the 
posterobasal and lateral left ventricular walls [4, 23]. As cardiomyocytes undergo 
apoptosis, they are replaced by the extracellular matrix (ECM). Subsequently, 
matrix metalloproteinases promote the degradation of ECM proteins, including 
collagen [24]. The increase in cytokines, chemokines, and degraded ECM debris 
stimulates an immune response, attracting neutrophils and macrophages which 
eventually leads to myocardial scarring and fibrotic patches [4, 24]. In the heart, 
LV volume and wall stress progressively increase as fibrotic tissue causes thinning 
and stretching of the ventricular walls, decreasing contractility and cardiac output. 
These processes eventually lead to either clinically decompensated heart failure, 
pump failure, and/or sudden cardiac death due to ventricular arrhythmias [4, 9, 23].
3. Clinical manifestations and diagnosis
Initially, DMD presents very early in childhood and therefore it is paramount 
to diagnose and initiate treatment as early as possible. Symptoms of DMD can 
arise in patients as young as three years of age and typically involve progressive 
muscle weakness, often manifesting as difficulty with ambulation, gait instability, 
difficulty climbing stairs, and enlarged calf muscles (or calf pseudohypertrophy). 
Additional presenting symptoms include scoliosis with or without back pain, 
fatigue, dyspnea secondary to diaphragmatic muscle weakness and/or cardiomy-
opathy, and arrhythmias [4, 25, 26]. The Gower’s sign, the act of a child using their 
hands to help prop themselves up into a standing position, is also a very common 
indicator of DMD [9, 25, 26]. These signs and symptoms suggest the possibility of 
underlying DMD and necessitate further diagnostic testing.
Key initial diagnostic tests include measurements of serum creatine kinase 
(CK) and liver transaminases (such as alanine aminotransferase, aspartate amino-
transferase) [27]. When levels of these biomarkers are elevated, DMD should be 
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suspected, and confirmatory genetic testing should be pursued. Genetic analysis via 
multiplex ligation-dependent probe amplification (MLPA) and genetic sequencing 
can help verify the presence and type of neuromuscular disorder [9, 27]. This is a 
critical step in diagnosis and is essential in informing which genetic therapies might 
be viable therapeutic options. On occasion, genetic testing yields no mutations in 
the DMD gene, or false negatives. In these instances of strong clinical suspicion 
of DMD with negative genetic test results, a muscle biopsy should be performed 
to assess for the absence of the dystrophin protein by immunohistochemistry [9]. 
Diagnosis of DMD occurs once genetic analysis and/or the biopsy confirms the 
absence of DMD.
However, diagnosing cardiac involvement in DMD is somewhat more challeng-
ing. Many of these patients are wheelchair-dependent and non-ambulatory well 
before adulthood, and as a result, patients are often asymptomatic until they have 
developed advanced disease [9, 28]. Studies report that approximately 25% of DMD 
patients develop cardiomyopathy by 6 years of age, and that percentage grows to 
almost 60% by age 10 [9, 29, 30]. Progression of cardiomyopathy often accelerates 
as patients age and nearly all DMD patients are expected to have clinical cardiac 
involvement by age 18 [7, 30]. Recognition and treatment of cardiomyopathy 
early in the disease course correlate with improved outcomes and more favorable 
ventricular remodeling, rendering it crucial to identify cardiac involvement as 
early as possible [1, 9, 23]. For this reason, guidelines strongly suggest including 
a cardiologist as a member of the care team from disease onset [4, 25, 31]. The 
2018 DMD Care Considerations, presented by the Center for Disease Control and 
Prevention, recommends that cardiac care and assessment are essential at the time 
of diagnosis [25, 31]. While previous guidelines have recommended consulting 
with cardiologists every two years, it is now strongly recommended that DMD 
patients receive cardiac assessment and screening at least every year starting from 
 diagnosis [25, 31].
Development of myocardial fibrosis along with ventricular dilation reflects 
myocyte destruction and progression in the underlying cardiomyopathy. Fatigue, 
nausea, dyspnea, palpitations, tachycardia, and chest discomfort may all represent 
symptomatic manifestations of DMD-associated cardiomyopathy, though many 
patients remain asymptomatic until later stages in life [31]. Therefore, the use of 
standard cardiac tools as well as high fidelity cardiac imaging are essential to accu-
rately diagnose cardiac involvement in patients with subclinical disease [1, 25].
Electrocardiograms (ECG) should be among the first tests performed, and 
results are often abnormal in DMD patients, correlating with morphological 
changes in cardiac muscle [23]. Screening ECG usually reveals tall R waves and deep 
Q wave irregularities in the anterolateral leads, which typically suggest lateral wall 
scarring (Figure 2A–C) [29, 32].
The ECG may be suggestive of cardiac involvement; however, cardiac imaging 
is essential to diagnose and monitor progression of cardiac involvement in DMD 
patients. While echocardiography has been a mainstay in diagnostic cardiac imaging 
for years, studies in patients with DMD have demonstrated that echocardiograms 
often underestimate both LV cavity volume and function and are much less sensi-
tive compared to cardiac magnetic resonance imaging (cMRI) in detecting wall 
motion abnormalities and overall cardiac function [9, 25, 32]. cMRI has been shown 
to be more accurate in assessing cardiac abnormalities in the setting of altered body 
habitus in DMD patients due to scoliosis, and it is considered the gold standard 
for cardiac imaging in DMD patients [25, 32]. The presence of late gadolinium 
enhancement (LGE) on cMRI indicates various degrees of myocardial inflamma-
tion, fibrotic scarring, and myocyte damage [25, 32]. In addition, LGE is often 
present before there is any clinically detectable deterioration in cardiac function or 
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symptoms of cardiomyopathy [25, 32]. When LGE is present, its distribution and 
change over time can be particularly effective in tracking cardiomyopathy progres-
sion [25, 32]. Finally, cMRI provides the most sensitive assessment of cardiac size, 
mass, and function, which can similarly be serially monitored to assess for progres-
sion of cardiac damage and response to medical therapy. Current DMD guidelines 
recommend a baseline cMRI to be performed between 8 and 10 years of age and 
repeated approximately every 2 years thereafter [25, 31]. Figure 3 depicts represen-
tative cMRI images in a DMD patient and an age-matched healthy control patient.
In cMRI, the technique of strain imaging has also been shown to be highly 
sensitive in gauging LV ejection fraction (LVEF) and cardiac dysfunction, especially 
when circumferential strain imaging is used [33]. Deviations in strain imaging can 
be indicative of cardiac dysfunction, and these abnormalities are common in DMD 
patients, even when LVEF measures are normal. Use of cMRI strain imaging, along 
Figure 2. 
ECG changes at various stages of DMD-associated cardiomyopathy. (A) DMD patient with normal cardiac 
function. (B) DMD patient with moderate LV systolic dysfunction. (C) DMD patient with severe LV systolic 
dysfunction and biventricular heart failure.
Figure 3. 
Structural differences in DMD-associated cardiomyopathy. Representative 4-chamber cMRI images in  
(A) a DMD patient and (B) a healthy age-matched control patient.
7
Clinical Management of DMD-Associated Cardiomyopathy
DOI: http://dx.doi.org/10.5772/intechopen.98919
with the presence of LGE, can provide valuable diagnostic and prognostic informa-
tion about a patient’s cardiac condition beyond simple measurements of contractile 
function [9, 33].
While cMRI has become the preferred imaging modality in DMD patients, there 
are still barriers to widespread adoption and utilization of cMRI. High procedural 
cost limits accessibility of cMRI, and the procedure can be challenging for younger 
patients and patients with claustrophobia [1, 25]. Furthermore, muscular weakness, 
spinal abnormalities, and restrictive lung disease can often make it difficult to fully 
assess cardiac structure and function using any of the available imaging techniques, 
but especially echocardiogram (ECHO) [9, 25, 32]. Therefore, if a cMRI can not be 
obtained the next ideal cardiac imaging tool that can be used is a cardiac CT scan 
with IV contrast, followed by 3D-ECHO with contrast.
The need for comprehensive cardiovascular assessment in DMD patients is 
undisputed, but there is also a significant risk for cardiovascular disease in DMD 
carriers [9, 25]. Mothers and sisters of patients who have been diagnosed with DMD 
should undergo both genetic testing to determine carrier status and evaluation by 
a cardiologist, preferably a heart failure specialist, to determine presence of heart 
disease. Recent studies have shown an increased risk of cardiac involvement in 
approximately 50% of DMD carriers, despite the presence of a functional DMD 
gene [9, 23, 34, 35]. For this reason, mothers and sisters of patients who have been 
diagnosed with DMD should undergo both genetic testing to determine carrier 
status and evaluation by a cardiologist, preferably a heart failure specialist, to 
determine presence of heart disease.
4. Pathophysiology underlying DMD-associated cardiomyopathy
Prior studies of DMD patients have demonstrated early cardiac involvement, with 
cardiac manifestations present in approximately 25% of DMD patients by 6 years of 
age and nearly universal cardiac involvement by 18 years of age [29, 30, 36]. These 
DMD patients go on to develop progressive cardiomyopathy as loss of dystrophin 
within cardiomyocytes results in ongoing cell death, leading to cardiac fibrosis and 
impaired cardiac function.
The pathologic mechanism underlying heart failure in the DMD population has 
not been fully elucidated. It is proposed that pathologic remodeling of the heart 
occurs as a result of both structural and metabolic abnormalities [37]. The mecha-
nism underlying both ischemic and non-ischemic cardiomyopathy is the develop-
ment of pathological cardiac hypertrophy, which eventually leads to paradoxical 
maladaptive cardiac remodeling [38]. Overtime, this compensatory mechanism 
fails and leads to cardiac dilatation and clinical heart failure [38]. Today, significant 
strides have been made in treating congestive heart failure (CHF), particularly 
systolic heart failure. Blockade of the renin-angiotensin-aldosterone system and 
inhibition of sympathetic activation have largely been the primary modes of 
treating a cardiomyopathy and inducing reverse cardiac remodeling. At least in 
non-ischemic cardiomyopathy patients on optimal medical therapy, approximately 
one third of patients will achieve normalization of the LV ejection fraction (LVEF), 
one third of patients will have improvement in the LVEF and the latter one third of 
patients will have progression in the LVEF requiring assessment for advanced heart 
failure therapies [i.e. implantation of a LV assist device (LVAD) or a heart trans-
plantation]. Thus, the standard of care for treatment of a cardiomyopathy is based 
on the development of pathological cardiac hypertrophy, which eventually leads to a 
dilated cardiomyopathy when left untreated. This approach to treating a cardiomy-
opathy has been extrapolated to the treatment of DMD-associated cardiomyopathy.
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Although pathological cardiac hypertrophy has been assumed to be the primary 
mode of maladaptive cardiac remodeling in DMD-associated cardiomyopathy, clini-
cal data suggests the use of guideline-directed medical therapy is not as effective in 
DMD-associated cardiomyopathy as it has been in other forms of cardiomyopathy 
with a reduced ejection fraction. Despite the increasing utilization of current 
standard of care heart failure therapies and device therapies, DMD-associated 
cardiomyopathy poses greater morbidity and mortality than other dilated cardio-
myopathies and remains the leading cause of mortality in the DMD population [32]. 
Accordingly, the mechanism of maladaptive cardiac remodeling has been increas-
ingly called into question. A cMRI study recently completed at UT Southwestern 
Medical Center suggests that adult DMD patients have small, atrophic hearts 
as compared to age-matched and weight-matched patients with non-ischemic 
cardiomyopathy or healthy patients enrolled in the Dallas Heart Study and this 
manuscript is currently under scientific review [39]. In an effort to further eluci-
date the mechanism leading to cardiac remodeling in DMD patients, the Mammen 
Laboratory at UT Southwestern Medical Center has discovered a proliferative defect 
in cardiomyocytes lacking dystrophin as early as four days postnatally in DMDmdx 
mice. This work was presented at the 2019 American Heart Association Scientific 
Sessions meeting and the manuscript is also currently under scientific review [40]. 
The mechanism into how a proliferative defect within neonatal DMD cardiomyo-
cytes leads to the eventual development of a DMD-associated cardiomyopathy in 
adult DMD patients is actively being investigated. These studies provide supportive 
data that the mode of maladaptive cardiac remodeling leading to DMD-associated 
cardiomyopathy, as illustrated in Figure 4, may be substantially different as 
compared to the mechanisms underlying non-ischemic cardiomyopathies. Once the 
signaling pathways governing these processes are better understood, appropriate 
Figure 4. 
Proposed mode of maladaptive cardiac remodeling leading to DMD-associated cardiomyopathy.
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targets for pharmacotherapy can be identified and allow for the development of 
novel drugs that can substantially improve the overall morbidity and mortality in 
the DMD population.
5. Management and treatment of DMD-associated cardiomyopathy
The majority of current therapies for DMD-associated cardiomyopathy col-
lectively induce reverse cardiac remodeling and alleviate symptoms of the disease. 
Recent guideline documents have attempted to shift the focus of care to more proac-
tive measures over the past decade [9, 25, 32, 41, 42]. These treatments include both 
pharmacological and non-pharmacological approaches.
5.1 Pharmacological treatments
The four major drug classes used to treat DMD-associated cardiomyopathy 
include angiotensin-converting-enzyme (ACE) inhibitors or angiotensin II recep-
tor blockers (ARB), beta-adrenergic receptor blockers, mineralocorticoid receptor 
antagonists (MRA), and corticosteroids (Table 1).
ACE-inhibitors are a first line class of medications used to treat DMD-associated 
cardiomyopathy [1, 43]. Studies have shown that the use of ACE-inhibitors in 
DMD patients specifically can delay the onset and progression of DMD-associated 
cardiomyopathy [23, 43, 44]. In addition, teenage DMD patients started on a 
beta-blocker and an MRA along with an ACE-inhibitor have significantly increased 
LVEF compared to untreated control subjects [43, 45]. Therefore, as outlined in 
the 2017 scientific statement by the American Heart Association, as well as by the 
DMD Care Considerations Working Group in 2018, it is strongly recommended that 
all DMD patients should be treated with an ACE-inhibitor beginning by the age of 
10, regardless of the presence of LV dysfunction [4, 41, 43, 46]. However, at the 
discretion of the physician and the family, an ACE-inhibitor may be started earlier 
depending on the results of cMRI studies [25, 32, 46]. The most commonly pre-
scribed ACE inhibitors in this population include enalapril and lisinopril [4, 43, 44].
Drug Class Examples
Beta-Adrenergic Receptor Blockers Carvedilol, Metoprolol Succinate, Bisoprolol
Angiotension-Converting-Enzyme Inhibitors Perindopril, Enalapril, Lisinopril
Angiotension II Receptor Blockers Candesartan, Losartan, Valsartan
Mineralocorticoid or Aldosterone Receptor Antagonists Spironolactone, Eplerenone
Steroids Prednisone, Deflazacort
Angiotension II Receptor-Neprilysin Inhibitor Sacubitril/Valsartan
Vasodilators Isosorbide Dinitrate/Hydralazine
Diuretics Furosemide, Bumetanide, Torsemide
Cardiac Glycosides Digoxin
Sodium-Glucose Co-Transporter-2 Inhibitors Canagliflozin, Dapagliflozion, 
Empagliflozin
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While ACE-inhibitors are still widely prescribed, their use may be limited by side 
effects in certain patients, including dry cough and the development of hyperkalemia. 
The use of an ARB is an effective and safe alternative medication to an ACE-inhibitor 
and its mechanism of action is also mediated by inhibiting the renin-angiotensin 
aldosterone signaling pathway [4, 23]. Thus, ARBs are often prescribed as alterna-
tive cardioprotective class of medications in DMD patients who experience adverse 
reactions to ACE-inhibitors [1, 47, 48]. These data are in line with large double-blind 
randomized clinical trials looking at the efficacy of ARBs versus ACE-inhibitors in 
patients with either non-ischemic or ischemic cardiomyopathies [49].
MRAs are another class of medications that have been shown to have beneficial 
effects specifically in DMD-associated cardiomyopathy. The combined use of a 
MRA and an ACE-inhibitor has been shown to improve cardiac function in DMD 
patients in a randomized clinical trial [1, 4, 23]. In particular, eplerenone adminis-
tered in conjunction with an ACE-inhibitor has been demonstrated in a clinical trial 
to significantly decrease ventricular circumferential strain in the treatment group 
compared to placebo [4, 50]. While spironolactone is a more potent MRA, eplere-
none interferes less with the androgen receptor and has a more favorable side effect 
profile as compared to spironolactone [4].
Beta-adrenergic receptor blockers are another drug class frequently utilized 
in treating DMD-associated cardiomyopathy. Beta blockers, are commonly used 
in conjunction with ACE-inhibitors/ARBs and MRAs to improve clinical cardiac 
outcomes and induce reverse cardiac remodeling in DMD [4, 23]. Although there is 
no double blind clinical trial demonstrating the beneficial effects of combination 
therapy in DMD-associated cardiomyopathy, there are several non-randomized 
clinical studies in the DMD population supporting the use of combination therapy 
[51–54]. In one particular study, survival rates of those on carvedilol was found 
to be higher than the control group, data consistent with many large randomized 
clinical trials on the beneficial effects of beta-blockers [55]. The beneficial effects 
of this combinatorial therapy are both additive as well as synergistic in regards to 
inducing reverse cardiac remodeling and delaying cardiomyopathy progression in 
DMD-associated cardiomyopathy [23].
Corticosteroids are also very commonly used in DMD patients to improve ambula-
tion, and are initiated early in the disease course, typically between 2 to 5 years of age 
[56–58]. Corticosteroids are primarily used to manage skeletal muscle wasting and are 
intended to improve muscle strength and ambulatory capacity in DMD patients [56]. 
However, long-term corticosteroid use is associated with significant adverse effects in 
DMD patients, including delayed puberty, decreased bone density, weight gain, devel-
opment of type II diabetes, and risk of developing systemic infections [42, 59–61]. A 
recent retrospective study, revealed DMD patients on a corticosteroid had a higher 
LVEF and greater chance for survival, though study limitations prevent one from 
drawing a direct correlation between corticosteroid use alone and mortality benefit 
given the confounding effect of co-administration of ACE-inhibitors in this study [62]. 
Further research is warranted to determine whether the clinical benefit of continued 
corticosteroid therapy outweighs the known significant side effect profile. Current 
guidelines recommend continuation of corticosteroid therapy except in patients who 
develop severe systemic infections or clinically significant osteoporosis [42, 60, 61].
Digoxin, a cardiac glycoside, comprises another class of medications used to 
treat DMD-associated cardiomyopathy. Digoxin has been used in conjunction 
with beta-adrenergic receptor blockers, ACE-inhibitors/ARBs, MRAs, and corti-
costeroids to reduce morbidity associated with DMD-associated cardiomyopathy 
[23, 63]. However, digoxin has fallen out of favor recently due to its adverse side 
effect profile and the lack of available data demonstrating clear clinical mortality 
benefit of digoxin administration in DMD patients [23].
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Other guideline directed therapies for heart failure (i.e. diuretics, isosorbide 
dinitrate/hydralazine, ivabradine, sacubitril/valsartan, and sodium-glucose 
co-transporter-2 inhibitors) have been shown to reduce morbidity and in some 
cases also mortality in patients with non-ischemic and ischemic cardiomyopathies 
(Table 1) [49, 64, 65]. The use of these medications in the treatment of DMD-
associated cardiomyopathy have not yet been studied, so the impact on morbidity 
and mortality is unclear in the setting of DMD patients. However, some of these 
medications are being judiciously used in select DMD patients with progressive, 
refractory DMD-associated cardiomyopathy.
5.2 Non-pharmacological treatments
As is the case in the treatment of non-ischemic cardiomyopathy, a number of 
non-pharmacological therapies exist for the treatment of DMD-associated cardio-
myopathy. These therapies include automated implantable cardioverter-defibrilla-
tors (AICD) with or without biventricular pacemaker capability, implantable left 
ventricular assist devices (LVAD) and heart transplantation. These treatments are 
most appropriate for DMD patients with end-stage heart failure who display signs 
of refractory disease, poor cardiac output, and/or severe conduction abnormalities. 
With the exception of AICDs, there is currently a lack of objective data regarding 
the benefits of LVAD implantation or heart transplantation in improving the mor-
bidity or mortality in this unique patient population. As such, current guidelines do 
not recommend routine incorporation of these non-pharmacological therapies in 
treating DMD-associated cardiomyopathy.
In multiple large clinical trials, AICDs have demonstrated a mortality benefit by 
decreasing the incidence of sudden cardiac death in non-ischemic and ischemic cardio-
myopathy patients with a LVEF less than 35% [49]. In addition, AICD implantation has 
been shown to reduce mortality rates in patients with sustained ventricular tachycardia 
or patients who have been resuscitated from sudden cardiac arrest [49]. The addition of 
cardiac resynchronization therapy to AICD implantation in patients with cardiomyop-
athy and a wide QRS complex has demonstrated improved morbidity and mortality in 
this patient population [66–68]. Therefore, the guidelines as set forth by the American 
College of Cardiology and the American Heart Association gave a Class I indication 
to the implantation of an AICD in patients with advanced heart failure and an LVEF 
less than 35% [49, 69]. These guidelines have been applied to DMD patients with 
cardiomyopathy and LVEF less than 35%, but in this unique population, special care 
and consideration must be taken into account when implanting an AICD given the high 
likelihood of significant muscle atrophy in the left upper portion of the chest [23, 25, 
70]. It is generally recommended that these patients be referred to an electrophysiolo-
gist with extensive experience in implanting devices in muscular dystrophy patients.
A LVAD is a form of mechanical circulatory support device that can be 
implanted into patients with advanced DMD-associated cardiomyopathy, either 
as a destination therapy or as a bridge to heart transplantation. While LVADs have 
been demonstrated to improve mortality in patients with advanced end-stage non-
ischemic and ischemic cardiomyopathy, approximately 20–30% of LVAD patients 
experience some complication within a year of implantation including infection, 
bleeding, and stroke [71–73]. Although LVADs have been implanted in DMD 
patients with advanced cardiomyopathy, the majority of these patients died within 
one year of LVAD implantation [74, 75]. As noted by Stoller et al., there are several 
essential or key factors that determine the long-term success of implanting a LVAD 
into DMD patients with advanced end-stage dilated cardiomyopathy (Table 2) [76].
Heart transplantation has been successfully undertaken in patients with 
muscular dystrophy. Both short and long term survival rates are very favorable 
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and comparable to age- and weight-matched cardiomyopathy patients without 
muscular dystrophy [77, 78]. However, there were only three DMD patients in both 
of these studies assessing the survival outcomes post-transplant. Due to significant 
skeletal muscle wasting in many DMD patients with advanced heart failure and 
restrictive lung disease, heart transplantation has only been undertaken in a lim-
ited number of DMD patients with advanced dilated cardiomyopathy, thus impair-
ing the ability to draw conclusions regarding outcomes post-transplant specifically 
in this patient population.
6. Emerging therapies and future directions
Despite the many gaps that still exist in cardiac care in patients with DMD, much 
progress has been made over the past two decades, and recent developments have 
paved the way for future therapies. In particular, gene-replacement and genome-
editing therapies hold significant promise due to the potentially corrective nature of 
these treatments by targeting the disease at the genetic level and restoring normal 
dystrophin levels.
Gene-replacement therapy using recombinant adenoviral virus vectors (rAVV) 
is one corrective method that has been proposed to treat DMD. This therapeutic 
approach is an especially promising therapy because this treatment modality has the 
potential to treat any underlying mutation within the dystrophin gene resulting in 
DMD disease and can therefore be applied to every DMD patient [4]. Since the full-
length DMD gene is too large to package within a rAVV, micro-dystrophins, which 
contain only the most essential parts of the gene, can be successfully packaged into 
a rAVV [79]. While this approach has had some success in preclinical and early 
clinical trials, there are still several drawbacks that have been observed, including 
heightened immune responses to the rAVV [79, 80]. Additionally, it is uncertain if 
the truncated micro-dystrophin protein will sufficiently improve cardiac function 
and reduce the burden of cardiomyopathy in DMD patients [4].
Key Factors Determining the Long-Term Success of a LVAD in a DMD Patient
Use of a multidisciplinary team pre- and post-LVAD implantation.
Appropriate candidate selection. While restrictive pulmonary physiology will be present, the DMD patient 
should not be on mechanical ventilatory support either pre-LVAD. In addition, the DMD patient should not 
have a GT-tube or PEG tube for supplemental feeding pre-LVAD.
Recognition of end organ dysfunction. DMD patients have very low baseline serum creatinine due to low 
muscle mass and even mild elevations are indicative of renal dysfunction. Conversely, liver function tests 
may be borderline elevated although further elevation, especially with evidence of volume overload, suggest 
right-sided heart failure in DMD patients.
An experienced cardiothoracic surgeon with significant expertise implanting LVADs into critically ill patients 
with advanced cardiomyopathy.
Selection of a LVAD that would not disrupt the diaphragm and thus further weaken the diaphragmatic 
muscle strength. This criteria is perhaps the most important factor that will determine the long-term success 
of a LVAD in a DMD patient and decrease the risk of any major medical complication.
Early extubation post-LVAD implantation with aggressive pulmonary toilet.
Aggressive care provided by physical, occupational, and respiratory therapy teams post-LVAD.
Very supportive and involved family.
Table 2. 
Essential factors determining the long-term success of an LVAD in DMD-associated cardiomyopathy. Adapted 
from [76].
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Antisense-mediated exon skipping using antisense oligonucleotides (ASO) is 
one type of genome editing therapy, which strives to restore the open reading frame 
caused by a frame-shift mutation [4, 81]. The restoration of the open reading frame 
is accomplished by targeting a specific mutated exon via an ASO, and then remov-
ing the mutated exon with spliceosomes. By sacrificing the single exon, the remain-
der of the gene can be restored and a functional, truncated dystrophin protein is 
expressed, with a phenotype more similar to that of Becker muscular dystrophy 
(BMD) [4]. While preclinical and clinical studies have demonstrated promising 
results and have led to the FDA approval of some of these therapies, clinical trials 
have shown only minimal restoration of dystrophin and limited effects on cardiac 
physiology due to inadequate delivery to and correction of cardiomyocyte dysfunc-
tion [81, 82]. However, recent research suggests that optimizing dosage and person-
alizing treatment may yield more promising results for treating DMD-associated 
cardiomyopathy, so it remains a potential option [23, 81]. As of March 2021, there 
are four ASO therapies (eteplirsen targeting exon 51, golodirsen targeting exon 53, 
viltolarsen targeting exon 50, and casimersen targeting exon 45) that have received 
FDA approval for the treatment of DMD. However, it remains unclear the long term 
benefits of these ASO therapies in treating the skeletal muscle dysfunction, the 
diaphragmatic weakness, and the cardiomyopathy that plague all DMD patients.
Genome editing utilizing clustered regularly interspaced short palindromic 
repeats (CRISPR) with CRISPR-associated protein 9 (Cas9) has emerged as 
another novel and exciting genetic approach to permanently treating DMD patients 
[83–90]. The clear advantages of CRISPR-Cas9 technology over antisense-mediated 
exon skipping are two-fold. First, using CRISPR-Cas9 mediated genome editing 
offers a one time permanent treatment for DMD. Second, CRISPR-Cas9 technol-
ogy provides highly sensitive and specific gene editing. This novel therapeutic 
method proposes delivery of the CRISPR-Cas9 machinery via adenoviral virus 
vectors (AVV). As such, this treatment also has the potential to trigger an unde-
sired immune response [89, 90]. The pre-clinical data demonstrates CRISPR-Cas9 
mediated genome editing remains a very promising and permanent correction to 
dystrophin deficiency in DMD patients [89–91].
Although all three of the above mentioned novel genetic therapeutic modali-
ties have generated significant enthusiasm by scientists, clinicians, and patients, 
there remains a fundamental flaw of these proposed therapies in relation to DMD-
associated cardiomyopathy. This flaw relates to the fact that they serve to functionally 
convert a DMD patient into a phenotype more closely resembling that of a BMD 
patient, rather than completely correcting or curing the DMD patient entirely of the 
disease process. While it is true that patients with BMD suffer less debilitating dis-
ease, approximately 70% of BMD patients over their lifespan still eventually develop 
advanced cardiomyopathy. Thus, while these novel genetic therapeutic modalities will 
surely improve the lives of DMD patients with improved skeletal muscle strength and 
mobility, challenges related to treating disease-related cardiomyopathy will persist [4].
Several other promising molecular therapies are also currently under investiga-
tion. Ataluren, an aminoglycoside-derived compound that functions as a stop-codon 
readthrough, is an investigational drug that has recently been approved by the 
European Medicine Agency, and is still being reviewed by the FDA [4, 92]. This ther-
apy works to continue translation of the gene past a premature stop codon. While 
results in preclinical trials have shown modest improvements in cardiac dystrophin 
levels, there has been little evidence so far of any actual cardiac benefit derived from 
this therapy in clinical trials [92, 93]. Stem-cell therapy holds significant potential as 
a therapeutic modality in treating DMD patients. In particular, induced pluripotent 
stem cells have shown promise, though there are barriers in terms of successful 
engraftment of these cells into DMD muscle as well as the process of differentiation 
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in-vivo [94]. Many potential future therapies such as these have focused on restor-
ing dystrophin levels in skeletal muscle and while this may improve skeletal muscle 
weakness and ambulation, it is essential to consider whether these therapies will also 
improve the accompanying cardiomyopathy.
Along with emerging therapies, new diagnostic measures have also been studied. 
One such diagnostic tool includes newborn screening (NBS), which involves measuring 
the creatine kinase (CK) levels among neonates [95, 96]. The CK levels are often mark-
edly elevated in newborns with DMD. The utilization of a two-tier system for testing, 
a cost-effective and accurate application of NBS, has been shown to have promising 
potential as a diagnostic tool to identify patients with DMD at an even earlier age [95].
In addition to these emerging therapies, there are many questions that have yet to 
be answered about existing treatments and therapies. Exact timing of initiation and 
dosage of first and second-line medications is still uncertain and remains disputed, 
though there is a broad consensus that earlier, anticipatory treatment is recommended 
for DMD patients [25, 43]. There is also a lack of supporting literature on beta-adren-
ergic receptor blockers, and more studies are needed to determine their exact benefits 
with and without the concurrent use of ACE-inhibitors or ARBs as well as MRAs [23].
Finally, DMD carriers are a relatively understudied and underappreciated 
group within this unique population of patients. DMD carriers are at significant 
risk for developing advanced cardiomyopathy, but the mechanisms underlying this 
phenomenon are unclear. The primary hypothesis is that skewed X chromosome 
inactivation occurs selectively within the cardiomyocytes of these patients, and one 
of the two X-chromosomes in the DMD female carrier becomes transcriptionally 
inactive [1, 34]. DMD carriers have an estimated 50% lifetime risk for developing 
cardiomyopathy [34, 97]. Researchers believe that the degree of X inactivation is 
correlated with the severity of cardiac manifestations in these patients, but better 
designed studies are required to understand the various mechanisms involved in the 
development of DMD-associated cardiomyopathy in DMD carriers [1].
7. Conclusion
Over the past two decades, tremendous progress has been made in understand-
ing the pathophysiology and treatment of DMD-associated cardiomyopathy. Due 
to advances in neurologic, pulmonary, and orthopedic care provided to DMD 
patients, there has been a significant increase in the life expectancy in these patients. 
Therefore, more DMD patients are living into adulthood resulting in cardiomyopathy 
as the primary mode of death in the majority of DMD patients in 2021. Current car-
diovascular guidelines directed specifically towards DMD patients are now available 
and provide a more solid foundation for evaluating and treating affected patients. 
Importantly, earlier recognition and management of the disease and its cardiac mani-
festations has great potential in slowing the progression of DMD-associated cardio-
myopathy. Part of this success is due to the incorporation of heart failure cardiologists 
into the multidisciplinary team approach to DMD care and the aggressive application 
of guideline directed medical therapy at an early age. Though there is much progress 
to be made, advancements in potential novel therapies and the growing body of 
research in this field have created a promising future for cardiac care in DMD.
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